drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR-T)
drug_description
Allogeneic donor-derived T cells engineered to express a chimeric antigen receptor targeting CD22; given sequentially post-transplant to address antigen-loss relapse and sustain leukemia control.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor-derived T cells are genetically engineered to express a CD22-directed chimeric antigen receptor. CAR engagement of CD22 on B-lineage leukemia cells triggers CD3ΞΆ/costimulatory signaling, activating T-cell cytotoxicity (perforin/granzyme) and cytokine release to eliminate target cells. Delivered sequentially post-allo-HSCT to mitigate antigen-loss relapse and sustain leukemia control.
drug_name
Donor-derived CD22 CAR-T cell therapy
nct_id_drug_ref
NCT06326008